Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Oncimmune revenue falls as it implements new strategy
(Sharecast News) - Oncimmune reported revenue of £2.1m in its final results on Thursday, down from £3.8m for the prior extended 15-month period, with revenue from continuing operations totalling £1.2m. The AIM-traded firm said gross profit for the 12 months ended 31 August stood at £1.5m, compared to £1.8m, while gross profit from continuing operations was £0.8m.
Administrative expenses decreased to £6.1m, with expenses for continuing operations amounting to £5m.
Notably, profit after tax reached £4.1m, primarily due to a gain on disposal of £12.2m, despite a loss from continuing operations of £6.2m.
The company's gross cash balance at the period end was £3.2m, and net debt stood at £2.1m following the disposal and partial repayment of the debt facility.
On the operational front, Oncimmune noted the ongoing implementation of a new strategy announced in October, with four new projects signed since the beginning of the 2024 financial year, three of which involved major pharmaceutical companies.
Revenue for 2024 was expected to reach £3m, representing a growth rate of 150% compared to the 2023 financial year.
Progress towards the target was evident, with 75% of forecast 2024 revenue secured by the end of the first half.
The board said the company's commercial team was nearing completion, with one additional hire expected in Europe during 2024.
It anticipated revenue growth to accelerate towards the end of 2024 and beyond as the new commercial team gained traction.
The new senior management team, in place for almost six months, had conducted a comprehensive review of the group's operational capability and cost base.
They anticipated lower overheads in 2024, including costs associated with senior management.
Moreover, new equity-based rewards for senior management were under consideration to align their interests more closely with those of the company's shareholders.
"Whilst 2023 has seen significant changes to the operations and management of Oncimmune, I remain encouraged and optimistic about the business outlook for 2024 and beyond," said chief executive officer Martin Gouldstone.
"During my first six months as CEO I, together with the rest of the senior management team, have carried out a root and branch review of the operations and financials of the business and have formulated a focused strategy to see the group reach revenues in its ImmunoINSIGHTS business not previously achieved.
"I have been pleased to see some of the strategies beginning to bear fruit and look forward to being able to report on more positive progress in the coming months."
At 1326 GMT, shares on Oncimmune Holdings were up 6.41% at 21.81p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.